(Q38056748)

27 August 2017

Bevacizumab in colorectal cancer: current and future directions (English)

1 reference

27 August 2017

1 reference

1 reference

1 reference

Yvonne Yeung

1

1 reference

27 August 2017

Niall C Tebbutt

series ordinal

2

1 reference

27 August 2017

language of work or name

1 reference

31 October 2012

1 reference

Expert Review of Anticancer Therapy

27 August 2017

1 reference

27 August 2017

12

1 reference

27 August 2017

10

1 reference

27 August 2017

1263-1273

1 reference

Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths

27 August 2017

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.104

Tumor angiogenesis: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.104

Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.104

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.104

Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.104

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.104

Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.104

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.104

Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.104

The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.104

A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.104

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.104

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.104

Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.104

Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.104

Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.104

First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.104

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.104

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.104

A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.104

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.104

Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuva

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.104

Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.104

Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.104

Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.104

Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.104

Modes of resistance to anti-angiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.104

21 January 2018

Identifiers

DOI

10.1586/ERA.12.104

1 reference

release_qjbd6bpcrbcghefdtbe6ysc7xi

27 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/qjbd6bpcrbcghefdtbe6ysc7xi

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference